Sunovion Pharmaceuticals Inc.

sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. the company has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions. sunovion’s track record of discovery, development and commercialization of important therapies has included brovana® (arformoterol tartrate), latuda® (lurasidone hci), and most recently aptiom® (eslicarbazepine acetate). headquartered in marlborough, mass. sunovion is an indirect, wholly owned subsidiary of sumitomo dainippon pharma co., ltd. sunovion pharmaceuticals europe ltd., based in london, england, and sunovion pharmaceuticals canada,